Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycaemia, which can cause micro-and macrovascular complications.
| INTRODUCTION
Diabetes mellitus is a global public health concern with rapidly increasing rates of morbidity and mortality. The disease has a high prevalence amongst adults aged 20-79, with an estimated 415 million people diagnosed in 2015, and an expected increase of 642 million people by 2040. 1 The most common form of diabetes mellitus is type 2 diabetes mellitus (T2DM), which has a 90-95% global prevalence. 2 Type 2 diabetes mellitus is a metabolic, chronic and multifactorial disease characterized by prolonged high blood glucose levels, known as hyperglycaemia. This arises due to (a) insulin resistance from insulin-responsive cells and tissues, (b) pancreatic β-cell dysfunction thus impaired insulin secretion or (c) the combination of both. 3 Environmental factors such as an unhealthy diet, sedentary lifestyle, old age and obesity, as well as genetic factors such as heritability, polymorphisms and mutations, are known to play a role in the development of T2DM. A diagnosis of T2DM further increases the risk of developing macrovascular (cardiovascular diseases) and microvascular (nephropathy, neuropathy and retinopathy) complications, unfortunately, unbeknownst to the diagnosed these complications can begin long before a diagnosis of T2DM is made, hence the high mortality rate of the disease.
Recent studies have also suggested that the interaction between environmental (lifestyle and nutrition) and genetic factors may play a role in the regulation of chronic inflammation, which may lead to T2DM and its related diabetic complications. The environmental factors can modulate gene expression via epigenetic modifications such as DNAm. 7 A genome-wide association studies (GWASs) identified genes which accounted for just 10% of the heritable risk for T2DM, whilst the remaining "missing" heritability could be contributed by rare variants, gene-environment interactions, gene-gene interactions and epigenetic factors. 8 Altered DNAm as well as decreased expression of metabolism genes and increased expression of inflammatory genes was observed in type 2 diabetic adipose tissue, thus suggesting a role of epigenetics in chronic inflammation associated with T2DM. 9 This review highlights cell and tissue gene expression changes, with focus on the potential role of epigenetic changes in chronic inflammation associated with T2DM (Table 1) .
| EPIGENETIC MODIFICATIONS
The epigenome is the chemical compound layer that surrounds the DNA and can influence gene expression within the genome, in response to environmental cues without altering the DNA sequence. Whilst epigenetics is fundamental in maintaining normal development and regulating cellular processes, 10 it is now widely associated with the risk and development of many diseases such as various cancers. 10 During early gametogenesis and immediately after fertilization, epigenetic marks undergo reprogramming. DNAm marks undergo genome-wide erasure followed by new set of DNAm marks. However, some DNAm does not undergo erasure and can be inherited. Evidence of epigenetic inheritance in mice has been documented; however, in human population, extent of epigenetic inheritance and its importance in human health and disease remains unclear. 11 As conclusive evidence of epigenetic inheritance in humans grows, potentially beneficial epigenetic modifications can be developed as preventative measures or therapeutic treatments for inflammatory diseases such as obesity and, T2DM.
12-14 Epigenetic modifications include DNAm, histone modifications, chromatin remodelling and non-coding RNAs, which are briefly discussed below.
| DNA methylation
The most commonly studied and well-characterized epigenetic modification is DNAm. DNAm involves the covalent addition of a methyl (CH 3 ) group to the 5-carbon position of a cytosine nucleotide pyrimidine ring by enzymes called DNA methyltransferases, resulting in a 5-methylcytosine. This mainly occurs at CpG dinucleotides. DNAm is essential for the regulation of developmental processes such as gametogenesis, embryogenesis, X-chromosome inactivation, genomic imprinting, etc. However, aberrant DNAm is linked to many diseases. 10, 15, 16 The promoter region of a gene generally contains a dense cluster of CpG dinucleotides which are collectively known as CpG islands and, if methylated is associated with transcriptional repression thus leading to decreased gene expression. The gene body, which is the region after the first exon, usually contains dispersed CpG dinucleotides and, if methylated is associated with increased gene expression. 17 DNAm can have permanent effects as it leads to long-term repression of gene expression in methylated regions of DNA. 
| Histone modifications
Histone modifications include covalent chemical modifications made post-translationally to histone proteins using specific enzymes. Histone modifications have important roles in transcriptional regulation and alternative splicing. These post-translational modifications include histone methylation/demethylation, acetylation/deacetylation, phosphorylation, ubiquitylation and sumoylation. Post-translational modifications of histone proteins influence gene expression by inducing changes in chromatin structure or by the recruitment of histone modifiers. 10 Histone methylation/demethylation and histone acetylation/deacetylation are the most common epigenetic histone modifications.
| Chromatin remodelling
Chromatin remodelling occurs when chromatin is rearranged from its tightly packed state to a loosened state, leaving DNA exposed to transcription factors or other DNA-binding proteins that influence gene expression.
19
ATP-dependent chromatin remodelling occurs when large macromolecular complexes use the energy from ATP hydrolysis to rearrange and alter nucleosomes resulting in transcription activation or repression. 20 Chromatin remodelling is carried out by enzymes used in DNAm and histone modifications, thus depicting a dependent relationship between these modifications.
| Non-coding RNAs
Non-coding RNAs (ncRNAs) play important roles in chromatin modification, transcriptional regulation and posttranslational regulation. 12 ncRNAs are divided into two classes, short ncRNAs and long ncRNAs. Short ncRNAs are involved in the regulation of messenger RNA (mRNA) transcripts and chromatin, and subclasses of short ncRNAs are involved in RNA interference (RNAi). 13 Long ncRNAs are known to control gene expression during both developmental and differentiation processes as well as mutations, and dysregulation of long ncRNAs seems to contribute to the development of many complex diseases. 13 Long ncRNAs are also found to be expressed in inflammatory 
T2DM
For many years, it was understood that the innate immune system's vital role was to fight against foreign pathogens that enter and harm the human body by causing infectious diseases. More recently, studies have suggested that the immune system is more than just a "bodyguard" but plays another role by interacting directly with metabolism, hence, the term "immunometabolism" was coined. 21 One of these interactive immune responses is inflammation, a defence mechanism in which a chemical response is released from immune cells that is white blood cells (WBCs) which eliminate or repair infection or injury to the body, with the goal of returning the infected or injured site back to its normal structure and function. Chronic inflammation occurs when the inflammatory process is continuous and is not due to a bacterial or a viral cause. In recent years, chronic inflammation is the common denominator in many diseases such as obesity, metabolic syndrome, T2DM, cardiovascular diseases, cancers, HIV/Aids, rheumatoid arthritis (and other autoimmune disorders). During the inflammatory process, the WBCs mainly secrete inflammatory cytokines which are signalling proteins that mediate and regulate inflammation. Proinflammatory cytokines initiate and upregulate inflammatory responses; however, overproduction of this can be harmful. In contrast, anti-inflammatory cytokines downregulate the effect of proinflammatory cytokines, however, overproduction of this may result in suppression of immunity. For example, proinflammatory TNF-α expression was found to be approximately 24 times greater in T2DM-prone A y mice than in wild-type mice. 22 Therefore, a balance in the production of pro-and anti-inflammatory cytokines is important to maintain the inflammatory process and immunity. 23 Metabolic diseases, such as metabolic syndrome, obesity and T2DM, trigger inflammatory responses as a coping mechanism towards metabolic changes, but if untreated leads to chronic inflammation ( Figure 1 ). 24 Interestingly, chronic inflammation is also associated with inducing metabolic changes in the body leading to diseases such as T2DM ( Figure 1 ). 24, 25 Obesity induces a metabolic inflammatory response leading to chronic inflammation in adipose tissue, and further causing insulin resistance-a root cause of T2DM. [25] [26] [27] Recent studies have attributed expression of inflammatory cytokines in T2DM to epigenetic changes, such as DNAm and histone modification/chromatin remodelling. 28 Differential methylation patterns have also been observed in genes relating more specifically to T2DM (not necessarily inflammatory genes), such as TCF7L2, SLC30A8, HNF1B and GLIS3. 29 Interestingly, in some studies, inflammation was detected in non-diabetic individuals suggesting that inflammation occurs earlier, prior to diagnosis of T2DM. 30, 31 Therefore, chronic inflammation may be the cause and result of T2DM and its related complications. Study of epigenetic alterations during inflammatory response, as a result of genetic and environmental signals, creates opportunities for the development of "early detection/relative risk" tests to aid in prevention of T2DM. Since some epigenetic changes are potentially reversible, targeting these changes might provide a means to slow down or revert the prevalence of T2DM.
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| CELL-SPECIFIC EPIGENETIC CHANGES ASSOCIATED WITH CHRONIC INFLAMMATION AND T2DM
WBCs account for about 1% of the total blood volume, yet they provide all the necessary protective and defensive mechanisms, for example inflammation, needed for immunity. WBCs are generally categorized into neutrophils, eosinophils, basophils, lymphocytes and monocytes. These different types of immune cells perform different functions, but their mode of action depends on the signals received from the injured or infected sites or from each other. The following section will focus on the studies related to gene expression and/or epigenetic changes in genes of WBCs primarily known to be involved in chronic inflammation and/or their association with T2DM.
| Neutrophils
Neutrophils contribute 50-70% of the total circulating WBCs in humans 32 and are the first to respond to inflammation at injuries or infections as they detect the chemical signals released from pathogens, a process known as chemotaxis. 32 As neutrophils play an important role in the inflammatory process and display quick response to changes in cellular environment, therefore understanding epigenetics' contribution to neutrophils will help in developing ways to use neutrophils in the prediction of/or as therapeutic targets for chronic inflammation associated with T2DM. Although at this stage, studies based solely on neutrophils and epigenetics in T2DM are rare, it is worthwhile to mention reports of other diseases which contribute to chronic inflammation and the role of epigenetics.
The neutrophil:lymphocyte ratio (NLR) is considered a well-established, easily accessible and affordable biomarker for chronic inflammatory diseases. 33 The link between the NLR and T2DM was unknown until the association of the NLR with the prevalence and incidence of T2DM was investigated. The study was performed on the Tianjin population, and the prevalence and incidence of T2DM were observed to be 4.9% and 6.8/1000 person-years, respectively. The mean NLR was positively correlated with the baseline NLR; therefore, the significant increase in the NLR level suggested that the NLR could be used as a predictive biomarker of T2DM. 33 In a cancer study by Koestler et al, 34 NLR in cancer patients using DNAm was estimated. Blood immune cells are characterized by difference in DNAm and leucocyte differentially methylated regions (L-DMRs) have been identified. 32, 33 Based on this information, the researchers developed a methylation-derived NLR (mdNLR) index using cell libraries of L-DMRs, followed by cell mixture deconvolution to estimate the fraction of immune cells. The developed mdNLR index was applied to cancer casecontrol studies of the bladder, head and neck, ovary and breast, as well as publicly available data on cancer-free subjects. 34 As expected, mdNLR scores were either elevated in cases relative to controls or associated with increased risk of death. 34 In future, similar study could be done for T2DM patients which will assist in developing methylation based assessment of T2DM progress. An interesting study by Ostuni et al 35 examined how epigenetic modifications regulate neutrophil development and function. DNAm analysis of neutrophils showed that the cells were mostly associated with unmethylated CpGs and cell-specific genes were also hypomethylated. 36 As exemplified in a previous report, 37 in normal neutrophils, aberrant expression of two autoantigens (PR3 and MPO) was suppressed by the expression of RUNX3 gene. However, in individuals with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), which is a group of inflammatory disorders affecting small blood vessels, hypermethylation of RUNX3 led to expression of PR3 and MPO. 37 A genome-wide gene expression study of peripheral blood leucocytes in lean and obese African Americans males showed that gene expression levels of neutrophil activation biomarkers, ELANE and MPO, were significantly increased in obese males when compared to lean males. 
| Monocytes and macrophages
Monocytes are the largest of all the WBCs. They are produced from bone marrow and circulate in blood for a few days before migrating and differentiating into macrophages in tissues, whereas some monocytes are reserved by the body in the spleen. 40, 41 Macrophages are known to stimulate the immune system and increase inflammation, and also decrease immune responses through the release of anti-inflammatory cytokines. 42, 43 Studies performed on macrophages may be difficult as obtaining the right tissue samples is not an easy task; therefore, circulating monocytes would be a better option for obtaining the material needed. CD16 + monocytes function to sense tissue injury and secrete cytokines during inflammation, and a significant decrease of CD16 + monocytes was seen in diabetic subjects with diabetic complications. 44 The study suggested that monocyte markers were altered in diabetics and could potentially be used to detect diabetic complications.
In an epigenetic study of monocytes, methylation status of CpG sites in the gene promoter of chemokine MCP-1 was investigated in non-diabetic and T2DM subjects. 45 MCP-1 is a chemokine that is linked with the development of cardiovascular diseases such as atherosclerosis in T2DM. DNAm may play a role in MCP-1 regulation by increasing its expression which leads to cardiovascular diseases. MCP-1 serum levels were found to be higher in T2DM subjects. MCP-1 promoter methylation was significantly correlated to serum MCP-1, HbA1c, fasting blood glucose and triglyceride. Hypomethylation was observed at CpG sites in the MCP-1 promoter region which may have been affected by blood glucose and triglycerides. 45 Paneni et al 46 reported that direct influence of histone modifications is due to SET -7 methyl transferases, in monocytes of T2DM patients. Set7 induces epigenetic changes on NF-kB p65 promoter of T2DM patients. The histone mark H3K4 m1 on NF-kB p65 promoter leads to expression of inflammatory genes and increased expression of NF-κB.NF-κB is a pleiotropic transcription factor involved in multiple biological functions, including inflammation, immunity, cell proliferation and apoptosis. 47 It is a master regulator of genes implicated in atherosclerosis and diabetes mellitus. 48 Macrophages can be divided into two distinct phenotypes depending on the stimuli they encounter: classically activated macrophages (CAMs) and alternatively activated macrophages (AAMs). CAMs are associated with chronic inflammatory diseases and T2DM, whereas AAMs are associated with pathogenesis of cancer, in parasite infections, allergy, wound repair and lung fibrosis. 49 In a dietinduced obesity (DIO) mouse model, DNA methyltransferase 3B (DNMT3B) enzyme was found to be lower in AAM than in CAM phenotype. DNMT3B knockdown resulted in an AAM phenotype resulting in suppression of macrophage inflammation. 50 Macrophages can also be separated into M1 and M2 depending on their surface markers. 51 Obesity has been shown to cause an imbalance between M1 and M2 adipose tissue macrophages (ATMs) causing an increase in proinflammatory cytokines which leads to metabolic diseases such as insulin resistance and T2DM. 52 Macrophage activation and insulin sensitivity are controlled by transcription factor PPARγ (peroxisome proliferator-activated receptorgamma). When activated, PPARγ promotes macrophage activation [53] [54] [55] whereas deletion of PPARγ leads to impaired macrophage activation and insulin resistance. 56 Based on this previous research, an epigenetic approach was taken to determine how obesity leads to defective ATM activation and how dysregulation of PPARγ leads to altered macrophage activation in obesity. Results showed that DNAm regulates ATM activation thus affecting inflammation. Using either 5-aza-2′-deoxycytidine or DNMT1, DNAm was inhibited in macrophages of mice which suppressed their inflammation. Mice with a DNMT1 deficiency displayed less macrophage inflammation thus had reduced obesity-induced inflammation and insulin resistance. Using the same inhibition methods on macrophage PPARγ promoter, macrophage activation was promoted and DNA hypermethylation was found to activate proinflammatory responses which increased inflammation therefore contributing to insulin resistance and obesity-like factors. 56 In another similar epigenetic study, DNMT3b regulated macrophage phenotype and inflammation from anti-inflammatory M2 to proinflammatory M1 obese profile. 57 Macrophages that were exposed to the saturated fatty acids as well as obese mice ATMs showed increased expression of DNMT3b. M2 macrophages had decreased expression of DNMT3b compared to M1 macrophages, which suggested that DNMT3b regulated macrophage phenotypes. A DNMT3b knockdown induced M2 phenotypes to decrease inflammation, and overexpression induced the M1 phenotypes to increase inflammation. A DNMT3b deficiency saw an improvement in adipocyte insulin signalling, suggesting that inactivation of macrophage DNMT3b likely downregulates macrophage inflammation, leading to improved insulin sensitivity. Unmethylated PPARγ1 promoter activity was higher than fully methylated promoter activity in macrophages, which suggested that PPARγ1 promoter activity was highly regulated by DNAm. A double knockdown of PPARγ1 and DNMT3b saw PPARγ1 blocked DNMT3b deficiency suppressed DNMT3b deficiencyinduced M2 macrophage polarization and anti-inflammatory phenotypes. Thus, DNAm at the PPARγ1 promoter using DNMT3b resulted in deregulated macrophage polarization, thus contributing to obesity-induced inflammation and insulin resistance. 57 A study on DIO mice model revealed that in T2DM, bone marrow progenitor cells undergo epigenetic modifications which preprogram the macrophages towards a proinflammatory phenotype. 58 Thus, the macrophages that leave the bone marrow are epigenetically altered. This, in turn, negatively effects wound healing. A histone mark named H3K27me3, which is associated with transcriptional repression, was decreased at the promoter of IL-12 gene in bone marrow progenitors thus leading to a significant increase in expression of IL-12, a key proinflammatory cytokine. This prolongs the inflammatory phase and complicates the healing process. The demethylase protein Jnjd3 was responsible for the decrease in methylation at H3K27. Thus, inhibition of Jnjd3 would potentially reverse status of methylation at H3K27me3 and IL-12 levels and could provide epigenetic-based therapy for efficient wound healing in T2DM. 58 A previous study extensively discussed how epigenetic modifications regulate macrophage activation in T2DM as well as how hyperglycaemia induces epigenetic changes that promote the increase of inflammatory macrophages. 43 
| Lymphocytes
Lymphocytes comprise of three cells types; T cells, B cells and natural killer (NK) cells.
Pro-and anti-inflammatory cytokines produced by T cells showed increased numbers of circulating IL-10, an anti-inflammatory cytokine, and IL-17, a proinflammatory cytokine, in CD3 + T cells in T2DM subjects. 59 The absence of DNMT1 or DNMT3a in murine CD4 + T lymphocytes caused defective gene silencing of inflammatory genes IFNγ and IL4 and DNAm marker MBD2, which led to increased cytokine expression. A similar trend was seen for Th2-type cytokine expression in CD8 + T cells, as defective gene silencing occurred in the absence of DNMT1. 60 In separate studies, DNAm had been found to regulate inflammatory genes IL-2, IL-4 and IFNγ in T cells. [61] [62] [63] Hypomethylation of cytokine loci which led to dysregulation of cytokine expression in murine T cells was found in the absence of DNMT3a. 64 Global DNAm in immune cells of three groups of subjects, healthy and non-diabetic lean, healthy and non-diabetic obese, and T2DM individuals, was compared. 65 No difference in DNAm was observed in PBMCs (consisting of both lymphocytes and monocytes) or in lymphocytes and monocytes separately amongst the three groups. However, B cells in obese subjects showed significant increase in methylation level when compared to lean controls (P = 0.012). In T2DM patients, a significant increase in methylation was observed in B and NK cells. Interestingly, the study also revealed that change in methylation in B lymphocytes is gene-specific as the promoter region of gene UBASH3A was found to be hypermethylated in T2DM subjects. 65 
| TISSUES-SPECIFIC EPIGENETIC CHANGES ASSOCIATED WITH CHRONIC INFLAMMATION AND T2DM
To obtain a greater, more holistic understanding of chronic inflammation in T2DM, the immune cells as well as the affected tissues involved in this process, must be studied in conjunction. Considering that different types of WBCs perform different functions, are structurally different and contain differentially methylated versions of the genome, they must each be studied independently. The same rationale is applicable to different tissues. The following section will focus more on epigenetic changes in tissues.
| Adipose tissue
One of the main comorbidities of T2DM is obesity, which is also the impetus behind an increased prevalence of T2DM. Adipose tissue produces proinflammatory cytokines in response to obese states that interfere with insulin signalling. 66 State of inflammation in adipose tissue promotes development of T2DM. A study by Tang et al 67 found that some non-repetitive regions in PGCs do not undergo epigenetic reprogramming and could be inherited, are enriched for genes associated with obesity-related traits. A gene that is most closely related to obesity and obesity-linked diseases such as T2DM is the fat mass and obesity-associated (FTO) gene. A study conducted by Terra et al 68 showed that anti-inflammatory serum adiponectin levels were positively correlated with FTO expression in subcutaneous adipose tissue (SAT). Furthermore, adiponectin levels in SAT as well as visceral adipose tissue (VAT) were also found to have a positive correlation to FTO gene expression in each respective tissue. Vaughan et al 68 found
that the inflammation-linked molecule, leptin, was inversely correlated with FTO expression in SAT. In addition, IL6, a proinflammatory cytokine, was also found to be negatively correlated with FTO expression. 69 Given that FTO has been found to play a role in demethylation of ssDNA and ssRNA, such as mRNA, 70 the correlation between expression of anti-inflammatory cytokines and FTO is possibly a result of demethylation of post-transcriptionally methylated mRNA. 71 Thus, leading to the increase in expression of anti-inflammatory cytokines, which in turn elicits a decreased ratio of proinflammatory cytokines in comparison to the anti-inflammatory cytokines which ultimately results in a neutral non-inflammatory state. An important player in obesity related inflammation is stearoyl-CoA desaturase 1 (SCD1), where the level of proinflammatory cytokine expression may be regulated by the methylation pattern of SCD1. 72 Global DNA hypomethylation is associated with overexpression of SCD1 and global hypermethylation leads to silencing of SCD1. Additionally, the promoter methylation pattern in CpG islands of IL-10 receptor antagonist (IL-10RA), IL-4 receptor antagonist (IL-4RA), IL-6 signal transducer (IL-6ST) and transforming growth factor β1 (TGF-β1) genes, was changed by SCD1 overexpression and correlated with changes in expression of the IL-10RA, IL-4RA, TGF-β1 and IL-6ST genes. 72 The role of DNMT3a as a mediator of adipose insulin resistance was reported. 73 Promoter hypermethylation was observed in FGF21, which facilitates glucose uptake in adipocytes and was inversely correlated with the expression of FGF21.
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Another contributing factor to chronic inflammation is hypermethylation of SLC19A1 in conjunction with the one carbon cycle (1CC). Global DNA hypermethylation in adipocytes derived from individuals in an obese state correlated with expression of genes involved in proinflammatory interactions. 74 Also, 1CC insulin resistance genes in vivo, as well as proinflammatory gene expression in white adipose tissue, were inversely correlated with SLC19A1 expression. Considering that the SLC19A1 codes for a protein that transports folate into and out of the cell, and the one carbon cycle requires a folate substrate to produce s-adenosylmethionine (SAM), which is a donor for DNAm, 75 it is possible that malfunctioning of the SLC19A1 gene may result in reduced regulation of folate leading to folate build-up. This excess folate would lead to mass production of SAM, which would result in hypermethylation of DNA. This is consistent with findings relating to SLC19A1 knockdown in human adipocytes, which lead to dysfunctional intracellular 1CC metabolism, and global DNA hypermethylation, which in turn brings increased expression of proinflammatory markers. 75 It is well understood that chronic inflammation results due to an imbalance between pro-and anti-inflammatory cytokines, with the latter being under expressed in comparison. Adiponectin, an anti-inflammatory cytokine, was found to be hypermethylated at 1 kb upstream of the promoter site of the adiponectin gene in adipocytes of obese mice fed with a high-fat diet. 76 The study was repeated using human adipocytes, and the results were found to be consistent Furthermore, DNMT1 expression in murine adipocytes was positively correlated with methylation of the adiponectin gene, resulting in decreased expression of adiponectin in obese mice, and increased expression in healthy mice. In human adipocytes, there was a correlation between DNMT1 expression and BMI, suggesting that obesity is a cause or cofactor of hypermethylation of the anti-inflammatory cytokine-adiponectin. 76 Aside from hypermethylation of anti-inflammatory cytokines, reactive oxygen species (ROS) has also been shown to be increased in adipose tissue of obese mice and is synonymous with human adipose tissue. 77 ROS modifies nuclear histone acetylation, as well as deacetylation. 78 These modifications then result in an upregulation of NF-κB-dependent expression of proinflammatory markers. 78, 79 In inflammatory diseases, NF-κB is phosphorylated and activation sustained by ROS to promote inflammation. 
| Spleen
The spleen is home to the mononuclear phagocyte system, which is inclusive of monocytes, macrophages and dendritic cells. 80 Splenic monocytes are capable of collectively being mobilized to other far off tissue types in response to inflammatory signals. Once the monocytes have infiltrated the tissue from which the inflammatory signal originates, they can differentiate into several types of macrophages and dendritic cells. 80, 81 A very recent report studied DNAm at the promoter of kruppel like factor 14 (KLF14) gene. 82 This gene regulates gene expression in adipose tissue and has association with T cell and macrophage differentiation. KLF14 exhibits maternal parent-of-origin effects, and thereby, its expression is under epigenetic control. 83, 84 KLF14 gene is normally expressed in the spleen, colon and kidneys. Previous GWAS studies have associated KLF14 gene with body mass index (BMI) and T2DM. [85] [86] [87] The effect of ageing and obesity on methylation profile of KLF14 promoter in 11 organs viz. the cerebrum, heart, lung, liver, pancreas, spleen, colon, kidney, testis (or the ovary), adipose tissue and whole blood of 20 young and 20 aged B6 mice was investigated. 83 Increased methylation levels in aged mice were observed on the lung (P = 0.009), spleen (P = 0.0007), kidney (P = 0.0007), colon (P = 0.006), adipose tissue (P = 6.3E-05), testis (P = 0.0005) and whole blood (P = 0.0008). Gene expression studies of the DIO mice model revealed significant reduction of expression in the spleen, adipose tissue and whole blood, thus indicating towards regulation of expression by methylation in these three tissues. Additionally, IL12, which is involved in the differentiation of naive T cells into Th1 cells, 88 was found to be drastically upregulated in the stromal vascular fraction (SVF) of adipose tissue. The authors suggested use of KLF14 promoter methylation as an epigenetic marker for chronic inflammation. 87 Aside from DNAm, another means of epigenetic control and possible treatment is chromatin remodelling. An investigation was carried out with the use of non-obese diabetic (NOD) mice, generally used in type 1 diabetes mellitus (T1DM) studies, to determine the effects of chromatin remodelling on the incidence of autoimmune diabetes. 76 The results indicated that treatment of female prediabetic NOD mice with histone deacetylase inhibitor (trichostatin A) lowered the occurrence of T1DM. Also, hyperacetylation of histones in pancreatic and splenic tissue was observed following treatment. 76 Despite the success of trichostatin A in inhibiting histone deacetylase and reducing the incidence of T1DM in prediabetic mice, this is not necessarily possible in individuals that are indefinitely diabetic, and histone/chromatin modifications having occurred whilst the individual was obese and/or hyperglycaemic may not be reversed. [89] [90] [91] Again, future studies involving chromatin remodelling in splenic tissue of T2DM-prone mice may illustrate a link or highlight the differences between T1DM and T2DM and the possible routes towards elucidating a means of prediabetic preventative treatment.
| Liver
In liver inflammation, hepatocytes are the main source of anti-inflammatory IL-1RA proteins. Production of IL-1RA by hepatocytes resulted in the resolution of hepatitis. 92 IL-1RA expression levels are highly elevated in obesity, supposedly to counteract the systemic inflammation that ensues, considering that IL-1RA is an anti-inflammatory cytokine. However, IL-1RA levels in fact correlate with insulin resistance and that halving the IL-1RA concentration in obese mice improves insulin sensitivity in the liver. 93 Though eliminating/supressing IL-1RA seems to pose as a feasible treatment for insulin resistance, studies indicate that removing circulating IL-1RA completely may lead to growth issues or illness. 93 Certain symptoms indicative of the metabolic syndrome (impaired glucose metabolism, fat accumulation and impaired lipid metabolism) are also amongst causes of injury to the liver. 94 Injury of liver cells results in the release of inflammatory cytokines by hepatocytes and biliary cells. The inflammation and accumulation of scar tissue in the liver then lead to liver fibrosis. 94 It was discovered during early stage liver fibrosis that the secreted phosphoprotein gene (SPP1) was hypomethylated. 95 This resulted in upregulated gene expression of SPP1, which induces inflammation and promotes tumorigenesis. An ongoing cycle of stimulation between inflammatory and fibrogenic cells ensues, leading to a chronic inflammatory state. 94 Hypomethylation may be a prelude to the onset of liver fibrosis and could therefore serve as a basis for an early means of detection for liver fibrosis. 95 Likewise, it could prove beneficial to elucidate the DNAm profile of chronic inflammatory markers in T2DM, considering that there is such a significant amount of overlap between liver fibrosis and chronic inflammation in T2DM. Besides diseases of the liver, certain diseases are most commonly age-related, such as T2DM, heart disease and cancer. However, today, younger individuals are at high risk for developing these diseases because of adolescent obesity.
A study made use of the "epigenetic clock" biomarker of ageing. It was found that obesity leads to premature epigenetic ageing of human liver tissue, which may explain why it is no longer only individuals of advanced ages that develop so called "age-related" diseases. 96 In addition to this, various studies have established that a high-fat diet induces chromatin remodelling in liver tissue as well as cultured hepatocytes. 97, 98 However, the regions within each genome that were targeted in the remodelling appear to be strain specific, 98 as the regions remodelled in C57BL/6J mice are not necessarily homologous with regions remodelled in DBA/2J mice. This implies that primarily irreversible genetics do play a regulatory role to some extent, even in epigenetic modifications, and thus still is a crucial piece of the puzzle that needs to be studied in conjunction with epigenetic mechanisms.
| CURRENT THERAPIES AND TREATMENT BASED ON INFLAMMATORY MARKERS
Studies by Sauter et al 98 and Ehses et al 99 used antiinflammatory cytokine interleukin-1 receptor antagonist (IL1RA) as treatment for inflammation-related T2DM in mice and rats, respectively. Mice on high-fat diet treated with IL1RA had improved hyperglycaemia, glucose tolerance and insulin secretion as well as overall β-cell functioning. 98 Rat treated with IL1Ra treatment saw improvement of hyperglycaemia and insulin resistance. 99 Islets and liver tissue also displayed decreased inflammation. 99 Larson et al 100 also used IL1RA treatment but in combination with the Anakinra protein. 100 Long-term treatment was found to have sustained improvement of β-cell functioning and inflammation. More research is much needed for the development of therapies, and treatments for epigenetics influenced inflammation-related obesity and T2DM.
| CONCLUSION AND FUTURE PERSPECTIVES
T2DM is already being treated from a pharmaceutical perspective, but treatment is not effective in treating inflammation (which accelerates disease progression), as the inflammation has no viral/bacterial cause. Changes in micro and macro environment manifest itself as epigenetic aberrations. Evidence of epigenetic inheritance in humans is sparse; however, future research into identification of heritable epigenetic changes may assist in early detection or prevention of T2DM based on the expression of inflammatory markers, and interpretation of their methylation profiles. This may come to fruition with the development of early detection kits of T2DM or chronic inflammation. Furthermore, potential gene-based therapeutic treatments may be developed and could be more specific and effective in treating chronic inflammation.
